The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study evaluates the safety and efficacy of intralymphatic allergen-specific immunotherapy
given to adolescents and young adults who are allergic to grass or birch pollen and have mild
or moderate asthma. Patients will be treated with three intralymphatic injections; 1000 SQ-U
x3 with 4-5 weeks interval, or placebo with 4-5 weeks interval. The patients receiving
treatment will be given a fourth injection one year after the initial injections. The study
is conducted in collaboration between Professor Lars Olof Cardell (ENT), prof Gunilla Hedlin
(Pediatrics) and prof Marianne van Hage (Immunology)".